<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109247</url>
  </required_header>
  <id_info>
    <org_study_id>19-261</org_study_id>
    <nct_id>NCT05109247</nct_id>
  </id_info>
  <brief_title>Prediction of Spontaneous Onset of Labor at Term</brief_title>
  <acronym>SOLPred</acronym>
  <official_title>Prediction of Spontaneous Onset of Labor at Term</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hologic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>QIAGEN Gaithersburg, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pregnolia AC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study intends to develop a predictive model of spontaneous onset of labor between 39 and&#xD;
      41 weeks of pregnancy in women carrying singletons and without indication of delivery before&#xD;
      this date. The main hypothesis is that a combination of clinical, ultrasonographic,&#xD;
      biochemical and/or biophysical variables will allow to differentiate women who will&#xD;
      spontaneously trigger their labors from those who will require an induction by the term of&#xD;
      their pregnancies. A tool of this kind should aid in the individualization of the management&#xD;
      of the final weeks of pregnancy and, at the light of recent evidence, provide support to the&#xD;
      decision-making processes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Weeks</target_duration>
  <primary_outcome>
    <measure>Spontaneous versus induced onset of labor</measure>
    <time_frame>3 weeks</time_frame>
    <description>Spontaneous onset of labor between the 39th and the 41st week of pregnancy versus induction of labor during the 41st week of pregnancy due to advanced gestational age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at spontaneous onset of labor</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time from sample collection at 39 weeks of pregnancy to spontaneous onset of labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at spontaneous onset of labor</measure>
    <time_frame>1 week</time_frame>
    <description>Time from sample collection at 40 weeks of pregnancy to spontaneous onset of labor</description>
  </secondary_outcome>
  <enrollment type="Anticipated">429</enrollment>
  <condition>Labor, Induced</condition>
  <condition>Labor, Obstetric</condition>
  <condition>Labor Onset</condition>
  <condition>Predictive Model</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women at 38+5 - 39 weeks of gestation who will deliver at the centers in which the&#xD;
        study will be carried out.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alive fetus&#xD;
&#xD;
          -  Singletons&#xD;
&#xD;
          -  Cephalic presentation&#xD;
&#xD;
          -  Intact membranes&#xD;
&#xD;
          -  Gestational age ≥ 38 weeks and 5 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fetal malformations&#xD;
&#xD;
          -  Symptomatic uterine contractions&#xD;
&#xD;
          -  Contraindication for vaginal delivery&#xD;
&#xD;
          -  Medical indication of induction of labor or elective cesarean delivery&#xD;
&#xD;
          -  Maternal desire to induce labor&#xD;
&#xD;
          -  Maternal negative to enrollment&#xD;
&#xD;
          -  Language barrier&#xD;
&#xD;
          -  Inability to give consent&#xD;
&#xD;
        Specific Exclusion Criteria for Pregnolia System (if any of these criteria is present, the&#xD;
        measurement of cervical stiffness using Pregnolia aspiration device will not be performed):&#xD;
&#xD;
          -  Müllerian anomalies with two cervices&#xD;
&#xD;
          -  Severe vaginal bleeding&#xD;
&#xD;
          -  Cervical dilatation&#xD;
&#xD;
          -  Known HIV&#xD;
&#xD;
          -  Visible, symptomatic cervical or vaginal infections&#xD;
&#xD;
          -  If one of the following conditions is present on the cervix at the 12 o'clock&#xD;
             position:&#xD;
&#xD;
               -  Nabothian cyst&#xD;
&#xD;
               -  Cervical myomas&#xD;
&#xD;
               -  Cervical condylomas&#xD;
&#xD;
               -  Squamous intraepithelial lesion&#xD;
&#xD;
               -  Conization/LEEP2/LLETZ3&#xD;
&#xD;
               -  Cervical endometriosis&#xD;
&#xD;
               -  Cervical tears&#xD;
&#xD;
               -  Cervical dysplasia&#xD;
&#xD;
               -  Large ectopy, for which it is not possible to find a suitable location near the&#xD;
                  ectopy where native tissue is present&#xD;
&#xD;
               -  Large scar tissue, for which it is not possible to find a suitable location near&#xD;
                  the scar where native tissue is present.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Federico E Migliorelli, MD, PhD</last_name>
    <phone>+34 607 31 32 57</phone>
    <email>Federico.Migliorelli@hcuge.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Begoña Martinez de Tejada, MD, PhD</last_name>
    <phone>+41 22 372 64 79</phone>
    <email>Begona.MartinezDeTejada@hcuge.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Desseauve, MPH, MD, PhD</last_name>
      <phone>+41 (0) 79 556 82 59</phone>
      <email>David.Desseauve@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franziska GEISSLER, MD</last_name>
      <phone>+41 61 328 58 84</phone>
      <email>franziska.geissler@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine McCarey, MD</last_name>
      <phone>+41 79 553 28 40</phone>
      <email>Catherine.Mccarey@hcuge.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Federico Migliorelli</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

